Trial · NCT01616524
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of subjects who achieve Sustained Virologic Response at post-treatment follow-up week 12 (SVR12) | Post-treatment follow-up week 12 | |
| Secondary | Proportion of subjects with Rapid virologic response (RVR) [undetectable Hepatitis C virus (HCV) Ribonucleic acid (RNA)] | On-treatment Week 4 | |
| Secondary | Proportion of subjects with treatment emergent cytopenic abnormalities (anemia as defined by Hb < 10 g/dL, neutropenia as defined by ANC < 750 mm3 or thrombocytopenia as defined by platelets < 50,000 mm3) | Up to week 12 or week 24 | Hb = Hemoglobin ANC = Absolute neutrophil count |
| Secondary | Proportion of subjects with on-treatment interferon-associated flu-like symptoms (as defined by pyrexia or chills or pain) | Up to week 12 or week 24 | |
| Secondary | Proportion of subjects with on-treatment musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain) | Up to week 12 or week 24 | |
| Secondary | Proportion of subjects with Sustained Virologic Response at post-treatment follow-up week 24 (SVR24) by treatment group | Post-treatment week 24 | |
| Secondary | Proportion of subjects with on-treatment Serious adverse events (SAEs) | Up to week 12 or week 24 | |
| Secondary | Proportion of subjects with dose reductions | Up to week 12 or week 24 | |
| Secondary | Proportion of subjects who discontinue due to Adverse events (AEs) | Up to week 12 or week 24 | |
| Secondary | Proportion of subjects with SVR12 in subjects with genotype-3 (GT-3) chronic HCV infection | Post-treatment follow-up week 12 | |
| Secondary | Proportion of subjects with on-treatment constitutional symptoms (fatigue or asthenia) | Up to week 12 or week 24 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01616524/registered